From Tumor Mutational Burden to Blood T Cell Receptor: Looking for the Best Predictive Biomarker in Lung Cancer Treated with Immunotherapy

SIMPLE SUMMARY: Immune control inhibitor drugs (anti-PD1/PD-L1/CTLA-4) (ICIs) are showing efficacy in the treatment of lung cancer. Currently the only biomarker with clinical utility for ICIs, such as the expression of PDL1, does not appear to be perfect or effective. Our working group is conducting...

Descripción completa

Detalles Bibliográficos
Autores principales: Sesma, Andrea, Pardo, Julián, Cruellas, Mara, Gálvez, Eva M., Gascón, Marta, Isla, Dolores, Martínez-Lostao, Luis, Ocáriz, Maitane, Paño, José Ramón, Quílez, Elisa, Ramírez, Ariel, Torres-Ramón, Irene, Yubero, Alfonso, Zapata, María, Lastra, Rodrigo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602200/
https://www.ncbi.nlm.nih.gov/pubmed/33066479
http://dx.doi.org/10.3390/cancers12102974

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602200/
https://www.ncbi.nlm.nih.gov/pubmed/33066479
http://dx.doi.org/10.3390/cancers12102974

Ejemplares similares